Metformina + Sitagliptina Aurovitas (Metformin Hydrochloride, Sitagliptin)

Metformina + Sitagliptina Aurovitas is used in the management of type 2 diabetes mellitus, targeting hyperglycemia through combined biguanide and DPP‑4 inhibition.

• Type 2 diabetes mellitus (monotherapy): Provides glycemic control when diet and exercise alone are insufficient.
• Type 2 diabetes mellitus (combination therapy): Enhances glucose lowering when added to other antidiabetic agents such as insulin or sulfonylureas.
• Type 2 diabetes mellitus (adjunct to lifestyle): Supports blood sugar management alongside diet, exercise, and weight‑loss interventions.

• Metformin acts primarily by inhibiting mitochondrial respiratory‑chain complex I, which reduces hepatic gluconeogenesis and increases peripheral insulin sensitivity. Sitagliptin selectively blocks the enzyme dipeptidyl peptidase‑4 (DPP‑4), preventing degradation of the incretin hormones GLP‑1 and GIP, thereby prolonging glucose‑dependent insulin secretion and suppressing glucagon release. The fixed‑dose combination delivers both actions simultaneously to improve overall glycemic control.

The most frequently reported adverse reactions and the less common but serious events associated with Metformina + Sitagliptina Aurovitas are listed below.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: loose stools, often transient.
• Abdominal discomfort: cramping or pain in the abdomen.
• Headache: mild tension‑type headache.

Serious or Rare Side Effects

• Lactic acidosis: rare but life‑threatening metabolic disturbance.
• Severe hypoglycemia: especially when combined with insulin or sulfonylureas.
• Pancreatitis: acute inflammation of the pancreas presenting with abdominal pain.

Before prescribing Metformina + Sitagliptina Aurovitas, clinicians should consider the following precautions.

• Renal function assessment: evaluate creatinine clearance to avoid metformin accumulation.
• Hepatic impairment: monitor liver enzymes as reduced function may increase risk of lactic acidosis.
• Risk of hypoglycemia: adjust dose of concomitant insulin or sulfonylureas to prevent low blood glucose.
• Pregnancy and lactation: use only if potential benefit justifies potential risk to the fetus or infant.
• Contraindications: avoid in patients with known hypersensitivity to either component.
• Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Metformina + Sitagliptina Aurovitas may interact with several medicines; interactions are categorized by clinical significance.

Major Interactions (Avoid)

• Renal impairment agents (e.g., iodinated contrast media): increase risk of metformin‑associated lactic acidosis.
• Insulin or sulfonylureas: may cause severe hypoglycemia when combined.
• Strong CYP2C8 inhibitors (e.g., gemfibrozil): can raise sitagliptin plasma levels.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask symptoms of hypoglycemia.
• ACE inhibitors or ARBs: concurrent use may affect renal function, requiring monitoring.
• Thiazide diuretics: can attenuate the glucose‑lowering effect of the combination.